Kevin C. Reilly - 08 Sep 2026 Form 4 Insider Report for KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS)

Reporting relationship: Director
Issuer ticker: KMTS
Reported as of: 08 Sep 2026
Net transaction value: -$73,677
SEC form: 4
Accepted by SEC: 10 Sep 2026, 20:26:55 UTC
Prior SEC filing: 12 Mar 2026
Source filing: View source filing
Reporting owner signature: /s/ Traci S. Umberger as attorney-in-fact for Kevin C. Reilly

Key filing fact

Kevin C. Reilly filed Form 4 for KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) on 10 Sep 2026.

Key facts

This page summarizes Kevin C. Reilly's Form 4 filing for KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS).
2 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 10 Sep 2026, 20:26.

Change

Previous filing in this sequence was filed on 12 Mar 2026.
Current net transaction value: -$73,677.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001958127 Primary reporting owner

Reilly Kevin C

Relationship: Director
Address: C/O ALLY BRIDGE GROUP, 430 PARK AVENUE 12TH FLOOR, NEW YORK
Signature: /s/ Traci S. Umberger as attorney-in-fact for Kevin C. Reilly
Signature date: 10 Sep 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

KMTS transaction

Common Shares

Sale

Transaction value: $73,677
Shares: -2,932
Change %: -35%
Price: $25.13
Shares after: 5,368
Date: 08 Sep 2026
Ownership: Direct
Footnotes: F1, F2

KMTS transaction

Common Shares

Award

Transaction value
Shares: +7,217
Change %: +134%
Price
Shares after: 12,585
Date: 09 Sep 2026
Ownership: Direct
Footnotes: F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

The sale reported in this Form 4 represents a nondiscretionary sale of shares required to be sold by the reporting person pursuant to sell to cover transactions to satisfy tax withholding obligations in connection with the vesting and settlement of restricted stock units.

Footnote F2

The price in Column 4 is a weighted average price. The prices at which the reported securities were sold ranged from $24.9100 to $25.3500. Upon request, the reporting person will provide to the Issuer, any security holder of the Issuer, or the SEC staff, information regarding the number of shares at each price within the range.

Footnote F3

The reported securities represent restricted stock units which each entitle the reporting person to receive one common share of the Issuer. The restricted stock units will vest on September 9, 2027, subject to the reporting person's continued service through such date.